Please upgrade your browser.
Kidney cancer patients who have only the tumor removed, not the entire kidney, have higher survival rates, a new study finds.
With the refinement of molecular and histologic classifications of renal neoplasms and the availability of more-effective molecular targeted therapy for specific renal neoplasms, immunohistochemical techniques will play an increasingly important role in the diagnosis of renal neoplasm. During the past few decades, many markers have been evaluated for their role in the diagnosis, prognosis, and prediction of treatment for renal neoplasms. The number of useful markers in our routine practice continues to increase.
70 percent of doctors reported that since they began practicing medicine, the bond with their patients has eroded.
This article will review the recent advances that form the current framework of therapy for RCC, as well as summarize key areas of progress and innovation in the evolving treatment paradigms for this disease.
Doctor Spiess specializes in treating kidney cancer patients. Linda was a perfect candidate for one of the new surgical treatments performed at The Moffitt Cancer Center.
Afinitor® approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
"Renal angiomyolipomas are one of the greatest causes of morbidity and mortality in adult TSC patients and can be one of the most challenging aspects of the disease to treat."
A rare form of cancer surfaces in Macomb County. It's not far from where a cancer cluster made several other kids sick in recent years.
Medical groups are warning that cancer patients in Wales, Scotland and Northern Ireland are not getting the same access to new drugs as patients in England.
The international Phase 3 ADAPT study is expected to commence in mid-2012 under a revised Special Protocol Assessment (SPA) agreement with the FDA. This pivotal study will evaluate the addition of AGS-003 to standard therapy versus standard therapy alone.
The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients...
|Powered by NeonCRM|